Tirzepatide 30mg
30mg
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has set new benchmarks in metabolic and weight loss research. As the compound behind some of the most significant findings in obesity science, tirzepatide demonstrates powerful effects on appetite regulation, glucose metabolism, and adipose tissue reduction. This 30mg vial provides researchers with an ample supply for comprehensive study protocols. Third-party HPLC tested. Lyophilised powder, requires reconstitution with bacteriostatic water.
Crypto payments only — How to pay guide
Documentation
COA-backed
Source
Manufacturer COA
Shipping
Australia-wide
Payment
Crypto only
RetaLABS Tirzepatide 30mg is a lyophilised research vial of LY3298176 — a dual GLP-1 and GIP receptor agonist. The 30mg vial aligns directly with the SURMOUNT-1 maximum dose of 15mg/week, providing two weeks of research supply at peak dose, or up to twelve weeks at the 2.5mg/week escalation starting point.
Supplied as a white lyophilised powder. Shipped via Express Post Australia-wide in discrete, unmarked packaging — typically dispatched within 1–2 business days of confirmed crypto payment (BTC, LTC, or XMR).
For reconstitution and storage guidance see the Peptide Reconstitution Guide. For SURMOUNT trial data and dosing schedules see the Tirzepatide Dosing Protocol.
Product Specifications
COA-backed, manufacturer-verified
Lyophilised powder
~4.8 kDa
-20°C (lyophilised), 2-8°C (reconstituted)
Bacteriostatic water or sterile saline
Available upon request
Research Use Only: These products are intended for laboratory research use only and are not approved for human consumption. All purchases are subject to our terms of service and local regulations.
Frequently Asked Questions
Everything you need to know about Tirzepatide 30mg